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Gastric inhibitory polypeptide (GIP) is released from the small intestine upon meal 
ingestion and increases insulin secretion from pancreatic β cells. Although the GIP 
receptor is known to be expressed in small intestine, the effects of GIP in small intestine 
are not fully understood. This study was designed to clarify the effect of GIP on 
intestinal glucose absorption and intestinal motility. Intestinal glucose absorption in vivo 
was measured by single-pass perfusion method. Incorporation of [
14
C]-glucose into 
everted jejunal rings in vitro was used to evaluate the effect of GIP on sodium-glucose 
co-transporter (SGLT). Motility of small intestine was measured by intestinal transit 
after oral administration of a non-absorbed marker. Intraperitoneal administration of 
GIP inhibited glucose absorption in wild-type mice in a concentration-dependent 
manner, showing maximum decrease at the dosage of 50 nmol/kg body weight. In 
glucagon-like-peptide-1 (GLP-1) receptor-deficient mice, GIP inhibited glucose 
absorption as in wild-type mice. In vitro examination of [
14
C]-glucose uptake revealed 
that 100 nM GIP did not change SGLT-dependent glucose uptake in wild-type mice. 
After intraperitoneal administration of GIP (50 nmol/kg body weight), small intestinal 
transit was inhibited to 40% in both wild-type and GLP-1 receptor-deficient mice. 
Furthermore, a somatostatin receptor antagonist, cyclosomatostatin, reduced the 
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inhibitory effect of GIP on both intestinal transit and glucose absorption in wild-type 
mice. These results demonstrate that exogenous GIP inhibits intestinal glucose 
absorption by reducing intestinal motility through a somatostatin-mediated pathway 




















Gastric inhibitory polypeptide (GIP), also called glucose-dependent 
insulinotropic polypeptide, is an incretin of 42-amino-acid polypeptide synthesized by 
K-cells of the duodenum and small intestine [1]. We previously generated GIP 
receptor-deficient mice (GIPR
-/-
 mice) and showed that GIPR
-/-
 mice have higher blood 
glucose levels as well as impaired initial insulin response after oral glucose load [2]. 
Thus, early insulin secretion stimulated by GIP plays an important role in glucose 
tolerance after oral glucose load.   
While GIP receptor mRNA was reported to be present in rat gut [3], the role of 
the GIP receptor in the gut has not been fully clarified. In the present in vivo study, we 
investigated the effect of exogenous GIP on intestinal glucose absorption in mice using 
the intestinal perfusion method. We investigated the effect of exogenous GIP on 
SGLT-dependent glucose uptake in vitro by using the everted jejunal ring method. 
Because intestinal motility and absorption are positively related [4, 5], we investigated 
the effect of exogenous GIP on gastrointestinal motility by non-absorbed marker 
method. Since SST secretion has been reported to be stimulated by GIP and to prolong 
intestinal motility, we also investigated the involvement of SST in the inhibitory effect 
of exogenous GIP on both intestinal transit and intestinal glucose absorption by using 
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somatostatin receptor antagonist. Our results demonstrate that exogenous GIP inhibits 
intestinal glucose absorption by reducing intestinal motility through a 










Materials and methods 
 
Animals 
Male C57/BL6J mice weighing 25 to 30 g (8-14 weeks old) were housed in a 
temperature (25±2℃)- and moisture (50%)-controlled room with a 12-h light/dark cycle 
(6:00 AM/6:00 PM). The mice were fed standard mouse chow (Oriental Yeast, Osaka) 
and tap water ad libitium, and used as wild-type mice. 
Generation of GIPR
-/-
 mice and GLP-1 receptor-deficient mice (GLP-1R
-/-
 
mice) was described previously [2, 6]. GLP-1R
-/-
 mice were kindly provided by Dr. 




 mice were used in the 
experiments. The Animal Care Committee of Kyoto University Graduate School of 
Medicine approved animal care and procedures.  
 
Materials 





(CSS) ) and 
somatostain 28 (SST) were from Sigma Chemical Co. (St. Louis, MO). All other 




Single-pass perfusion method [7] was used to measure the effect of exogenous 
GIP or SST on intestinal glucose absorption using C57/BL6J mice. Preperfusion was 
done for a 45-min equilibration period and the samples were discarded. Three 15-min 
samples were then collected. GIP or SST was administered intraperitoneally at 60-min 
after starting the preperfusion according to the protocol (Fig.1A). The change of 
absorption was calculated as the glucose concentration of the first sample collected 
(Period 1) minus the glucose concentration of the last sample collected (Period 2), and 
expressed as per centimeter perfused bowel. Negative values indicate an inhibitory 
effect on absorption; positive values indicate an increased effect on absorption. 
 
Glucose uptake in jejunum in vitro 
Incorporation of D-glucose into everted jejunal rings was determined as 
described previously [8]. SGLT-dependent glucose uptake for 15-min was determined 
as the glucose uptake in the absence of phlorizin minus the glucose uptake in the 
presence of phlorizin.  
 
Small intestinal transit after intraperitoneal administration of GIP 
Transit through the stomach and small intestine was measured by administering 
a non-absorbed marker containing 10% charcoal suspension in 5% gum Arabic, as 
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previously described [9]. The mice were given 0.2 ml of the suspension by gavage 
through a straight blunt-ended feeding needle. GIP (50 nmol/kg body weight) or SST 
(75 nmol/kg body weight) or vehicle (saline) was administered intraperitoneally 15-min 
prior to the administration of the non-absorbed marker. CSS (1 µg/kg body weight), or 
vehicle (saline) was intraperitoneally administered 10-min prior to GIP administration.  
 
Plasma GIP and SST assays 
 Blood was collected from the tail vein before the intraperitoneal administration 
of GIP (50 nmol/kg body weight) and collected again 20-min after the administration. 
ELISA assay kit was used according to the manufacture’s instruction for the 
determination of plasma total GIP concentration (Linco Research, St. Charles, MO) and 
SST concentration (Phoenix Pharmaceuticals INC., Belmont, CA), respectively. 
 
Analysis 
The results are given as mean ± standard error (S.E.M., n=number of mice). 
Statistical significance was determined using paired and unpaired Student’s t-test and 
analysis of variance (ANOVA). P<0.05 was considered significant.   
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Results 
Perfusion experiment  
Inhibition of glucose absorption was calculated by change in glucose 
concentration in effluent perfusate in wild-type mice (Fig. 1A). Spontaneous inhibition 
of glucose absorption of 49 ± 44 nmol/cm/15min is shown in saline-administered 
controls (Fig. 1B). Inhibition of glucose absorption was enhanced to 67 ± 40, 163 ± 84, 
and 409 ± 96 nmol/cm/15min when the amount of intraperitoneally-administered GIP 
was increased to 12.5, 25, and 50 nmol/kg body weight, respectively.  
 
Glucose uptake by jejunum in vitro 
We investigated glucose uptake by the jejunum in vitro using everted jejunal 
rings. In the presence of 100 nM GIP in the incubation medium, glucose uptake into 
jejunal rings in wild-type mice was similar to that in the presence of vehicle (control: 
4.2 ± 0.9 μmol/g weight; GIP: 3.5 ± 0.9, P=NS; Fig. 2A). Additionally, glucose uptake 
into jejunal rings in GIPR
-/-
 mice was similar to that in wild-type mice (wild-type mice: 
4.0 ± 0.5 μmol/g weight; GIPR-/- mice 4.6 ± 0.7, P=NS; Fig. 2B). 
 
Small intestinal transit after intraperitoneal administration of GIP 
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Intestinal transit rate was measured by the length of small intestine traversed by 
the charcoal suspension. In wild-type mice, the intestinal transit rate in 
GIP-administered mice was significantly less than that in saline-administered control 
(45 ± 8% vs. 68 ± 4%, P<0.01; Fig. 3A). On the other hand, in GIPR
-/-
 mice, the 
intestinal transit rate was similar to that in saline-administered control and 
GIP-administered mice (65 ± 3% vs. 63 ± 4%; Fig. 3B).   
 
Perfusion and intestinal transit in GLP-1 receptor-deficient mice 
To determine whether GIP affects intestinal glucose absorption through GLP-1 
signaling, inhibition of glucose absorption by GIP was measured in GLP-1R
-/-
 mice. 
Inhibition of glucose absorption in GLP-1R
-/-
 mice was 44 ± 100 nmol/cm/15min in 
saline-administered control mice and 426 ± 104 nmol/cm/15min in GIP-administered 
mice (50 nmol/kg body weight, P<0.05, Fig. 3C). Thus, GIP significantly inhibited 
glucose absorption in GLP-1R
-/-
 mice.  
The intestinal transit rate was also evaluated in GLP-1R
-/-
 mice, and was 59 ± 
13% in saline-administered control and 42 ± 7% in GIP-administered mice, respectively.  
Thus, GIP significantly inhibited the intestinal transit rate in GLP-1R
-/-
 mice (P<0.01, 
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Fig. 3D). Consequently, the genetic disruption of GLP-1 receptor did not affect GIP 
action on intestinal glucose absorption and intestinal transit. 
 
Involvement of SST in the action of GIP  
To determine whether the inhibitory effect of GIP on intestinal transit is due to 
release of SST, a somatostatin receptor antagonist, CSS (1 µg/kg body weight), was 
intraperitoneally administered 10-min prior to GIP administration in wild-type mice 
(Fig.4A). In the presence of CSS, the intestinal transit rate in GIP-administered 
wild-type mice was significantly higher than that in the absence of CSS (60 ± 3% vs. 45 
± 8%; P<0.01). Accordingly, CSS reduced the inhibitory effect of GIP on intestinal 
transit. Moreover, intraperitoneally-administered SST itself significantly inhibited the 
intestinal transit rate in wild-type mice compared to control (SST: 37 ± 5% vs. control: 
68 ± 4%, P<0.01). 
In a perfusion experiment, to confirm that the inhibitory effect of GIP on 
intestinal glucose absorption is attributable to release of SST, CSS (1 µg/kg body 
weight) was intraperitoneally administered 10-min prior to GIP administration in 
wild-type mice (Fig.4B). In the presence of CSS, the inhibition of glucose absorption in 
GIP-administered wild-type mice was significantly lower than that in the absence of 
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CSS (410 ± 96 nmol/cm/15min vs. -290 ± 99 nmol/cm/15min; P<0.01). Accordingly, 
CSS reduced the inhibitory effect of GIP on intestinal glucose absorption. Furthermore, 
inhibition of glucose absorption in wild-type mice mice was 49 ± 44 nmol/cm/15min in 
saline-administered control mice and 278 ± 63 nmol/cm/15min in SST-administered 
mice (75 nmol/kg body weight, P<0.05). 
In an experiment of glucose uptake in everted jejunal ring, 100 nM SST did not 
alter glucose uptake compared to control (control: 4.2 ± 0.9 μmol/g weight; SST: 4.2 ± 
0.4, n=8; P=NS). 
 
Measurement of plasma GIP and SST levels 
The plasma levels of total GIP and SST in mice were significantly enhanced 
20-min after the intraperitoneal GIP-administration at a dosage of 50 nmol/kg body 
weight compared to the respective basal levels (GIP: 58 ± 5 pg/ml vs. 3400 ± 257 pg/ml, 
n=8; P<0.01; SST: 9.9 ± 0.5 ng/ml vs.11.9 ± 0.3 ng/ml, n=8; P<0.05).  
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Discussion 
We investigated the inhibitory effect of exogenous GIP on glucose absorption 
in small intestine. GIP has been known as an important insulinotropic hormone released 
from duodenal K cells. However, there have been few reports on the effects of GIP on 
intestinal glucose absorption. In the present study, GIP was found to inhibit glucose 
absorption in a concentration-dependent manner by the perfusion method. 
Glucose absorption includes two steps in enterocytes, permeation through 
brush-border membrane and subsequently through basolateral membrane. Glucose and 
galactose cross the brush-border membrane by means of SGLT-1, which is a 
rate-limiting step of glucose absorption [10]. Recent in vitro study by Singh et al. found 
that exogenous GIP stimulates SGLT-dependent glucose aborption by using an Ussing 
chamber experiment [11]. In the experiment, intestine was fixed between two chambers, 
and short-circuit-current representing SGLT activity was measured. However, in our 
experiments using everted jejunal rings, which is another method to measure 
SGLT-dependent glucose absorption in vitro, the lack of effect of exogenous GIP on 
SGLT-dependent glucose uptake was shown, and genetic disruption of the GIP receptor 
was found not to affect SGLT-dependent glucose absorption. The reason why our results 
and theirs are different is unknown, but may be attributable to difference in method. 
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It is generally accepted that there is a positive relationship between intestinal 
motility and absorption [4, 5]. It has been shown that increased intestinal motility, 
besides enhancing the functional surface area, facilitates diffusion of glucose to the 
transporters of the brush-border membrane by alterring the unstirred water layer [12, 
13]. We investigated the effect of GIP on motility of small intestine by evaluating 
intestinal transit. In the present study, GIP was found to inhibit intestinal transit 
compared to control in wild-type but not in GIPR-/- mice. Thus, the inhibitory effect of 
GIP on glucose absorption may be attributable, in part, to inhibition of intestinal 
motility.   
GLP-1, another incretin hormone, is secreted from L cells found predominantly 
in ileal mucosa, and is known to be part of the “ileal brake” that acts as an inhibitor of 
upper gastrointestinal motility [14]. In the present study, GIP was found to inhibit 
intestinal transit in GLP-1R
-/-
 mice as well as in wild-type mice, indicating that the 
inhibitory action of GIP on gastrointestinal transit is not mediated by GLP-1. 
Furthermore, glucose absorption was found to be inhibited significantly by GIP in 
GLP-1R
-/-
 mice as well as in wild-type mice, suggesting that the primary mechanism of 
the inhibition of intestinal glucose absorption by GIP most likely does not involve the 
GLP-1-mediated pathway. 
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Recently, Miki et al. reported that GLP-1 inhibited gut motility while GIP did 
not [15]. In the present study, however, GIP was found to inhibit intestinal transit. The 
inconsistency could be due to their use of a non-absorbed marker containing a high 
concentration (as much as 50%) of glucose to evaluate gut motility, whereas we used a 
non-absorbed marker without glucose. Intraduodenal infusion of hyperosmolar solution 
was reported to increase duodenal motility, which is mediated by activation of 
osmoreceptors in duodenum [16]. In our preliminary experiment on small intestinal 
transit using 10% charcoal suspension in 5% gum Arabic with 50% glucose, the 
intestinal transit rate was significantly greater than that when using glucose-free 
solution (88 ± 8% v.s. 68 ± 4%, P<0.05, unpublished data). Therefore, intestinal transit 
might be enhanced by the high concentration of glucose itself in the suspension, which 
could conceal a GIP-evoked inhibitory effect on intestinal transit. However, limitations 
of this study must be considered. While GIP was found to inhibit intestinal transit under 
the conditions of the present study, the effect of GIP on intestinal transit may differ 
among the constituents of the food or nutrient. Further investigations are required. 
Regarding the GIP dosage applied in the in vivo experiments, low GIP dosage 
has been used when applied by the route of continuous intravenous administration; GIP 
(0.25 nmol/kg body weight) was reported to stimulate insulin secretion by intravenous 
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administration in rat [17] and (GIP 4 pmol/kg body weight/min) in human [18]. 
However, high GIP dosage has been used when applied by the other routes of 
administration than intravenous administration. Indeed, one group has reported that 
subcutaneous pre-administration of 100 g GIP (approximately 800 nmol/kg body 
weight) lowered glucose excursion in oral glucose tolerance test in mice [15] and 
another group has reported that intraperitoneal administration of [D-Ala
2
]GIP (48 
nmol/kg body weight/day), a DPP4-resistant analogue, lowered glucose excursion in 
intraperitoneal glucose tolerance test in mice [19]. In the present study, we applied GIP 
intraperitoneally at a dosage of 50 nmol/kg body weight to demonstrate the 
pharmacological effects of GIP on intestinal transit and glucose absorption, which 
dosage is comparable to those used in the latter reports.  
Regarding the mechanism of inhibition of intestinal transit by GIP, SST 
secretion has been reported to be stimulated by GIP [20-22] and to prolong intestinal 
transit [23, 24]. The SST receptor has five isoforms (sst1-5) and all five receptors have 
been shown to be expressed in gastrointestinal tract, with high levels of sst2 receptor in 
intestine [25]. The sst2 receptors in intestine have been shown not to be expressed on 
enterocytes or muscle cells, but on myenteric and submucosal plexuses and on 
neuroendocrine cells in epithelium [26] and also on interstitial cells of Cajal in deep 
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muscular plexus [27]. Thus, the mechanisms by which exogenous GIP inhibits intestinal 
motility through two SST-mediated pathways may be as follows. In the first, exogenous 
GIP binds to the GIP receptors on the cell surface membrane in SST-containing enteric 
neurons and/or in mucosal endocrine cells of D cells in gastrointestinal tract and/or in 
pancreatic islets, resulting in the release of SST. Subsequently, the released SST acts as 
a neurotransmitter and binds to sst2 receptors expressed on other neurons in myenteric 
plexus, parts of which nerve fibers are distributed to muscular cells, permitting 
inhibition of intestinal motility. In this pathway, the local SST concentration in 
interneural synaptic space may be increased prominently. In an alternate pathway, SST 
secreted from D cells flows into systemic circulation through submucosal vessels to 
reach the neurons in myenteric plexus. Indeed, in the present study, 
intraperitoneally-administered GIP induced a small but significant increase in plasma 
SST levels, suggesting involvement of the latter pathway. 
In our experiment of intestinal perfusion, GIP was found to inhibit intestinal 
glucose absorption primarily by reducing intestinal motility. On the other hand, the 
tissue of everted intestinal ring is set inside-out and distended far from the physiological 
condition, and thus incapable of reflecting general intestinal motility. Thus, the lack of 
 19 
GIP action on glucose uptake in the tissues of everted intestinal ring in the present study 
may be expected. 
Several studies have found that the inhibitory effect of SST on intestinal 
glucose absorption may be attributable to either the effect of SST on the splanchnic 
hemodynamics [28] or a direct effect of SST on enterocytes [29]. However, consistent 
with the present study, another study has found that SST delays intestinal glucose 
absorption by its inhibitory effect on intestinal motility [24]. SST exerts its inhibitory 
effect on intestinal glucose absorption by several mechanisms; our results indicate that 
the inhibitory effect of SST is mediated, at least in part, by alteration of intestinal 
motility.  
In the present study, the somatostatin receptor antagonist CSS was found to 
reduce the inhibitory effect of GIP on intestinal transit, suggesting that GIP stimulates 
SST release. In addition, we show that SST itself inhibits intestinal transit and glucose 
absorption in perfused intestine. Consistently, a recent study has reported that SST 
inhibits intestinal glucose absorption [29]. Considered together with previous reports, 
we conclude that exogenous GIP inhibits intestinal transit and glucose absorption 
indirectly through a somatostatin-mediated pathway.   
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One of the physiological roles of GIP is known to be facilitation of nutrient 
uptake into adipose tissue and bone. In the present study, exogenous GIP was found to 
inhibit intestinal glucose absorption by reducing intestinal motility. Since this 
observation was obtained by the action of a supraphysiological level of plasma GIP, it is 
unclear whether or not the action is associated with already known physiological actions 
of GIP. In the point of delay of intestinal carbohydrate absorption, however, the 
biological action of GIP found in the present study appears to be similar to that of 
medical medicine -glucosidase inhibitor, which does not influence the regulation of 
energy accumulation in adipose tissue or bone. 
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Fig. 1 (A) Diagram showing the sampling protocol of intestinal perfusion. The flow rate 
of the perfusion fluid was 2 ml/15 min. Perfusion began with an equilibration period of 
45-min, which samples were discarded. The samples of Period 1 and Period 2 were then 
collected. GIP was administered intraperitoneally 60-min after the beginning of 
preperfusion. The change of absorption was calculated as the glucose concentration of 
the first samples collected (Period 1) minus the glucose concentration of the last 
samples collected (Period 2), and expressed as per centimeter perfused bowel. (B) 
Concentration-dependence of inhibition of glucose absorption by GIP in wild-type mice. 
Data are shown as means with S.E.M. (n=6 for each group, P<0.05 by ANOVA).   
 
Fig. 2 Glucose uptake in the jejunum. (A) Glucose uptake in the jejunum in wild-type 
mice in the absence and in the presence of 100 nM GIP. (B) Glucose uptake in the 
jejunum in wild-type and GIPR
-/-
 mice. SGLT-dependent glucose uptake was 
determined as the glucose uptake in the absence of 1mM phlorizin minus the glucose 
uptake in the presence of 1mM phlorizin. Data are shown as means with S.E.M. (n=8 
for each group). 
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Fig. 3 Intestinal transit after oral administration of non-absorbed marker (10% charcoal 
suspension in 5% gum Arabic) in wild-type (A) and GIPR
-/-
 (B) mice. Twenty minutes 
after administration of non-absorbed marker by gavage, the animals were killed and the 
entire gastrointestinal transit tract was removed. GIP (50 nmol/kg body weight) or saline 
was administered intraperitoneally 15-min prior to the administration of non-absorbed 
marker. Data are shown as means with S.E.M. (n=6 for each group). Statistical 
significance was determined using students’ t test. **P<0.01 compared with control. (C) 
Inhibition of glucose absorption in GLP-1R
-/-
 mice with or without intraperitoneal GIP 
administration as indicated in the legends of Fig 1. (D) Intestinal transit after oral 
administration of non-absorbed marker in GLP-1R
-/-
 mice with or without 
intraperitoneal GIP administration as indicated in the legends of Fig 3A. Data are shown 
as means with S.E.M. (n=6 for each group). Statistical significance was determined 
using students’ t test. *P<0.05 compared with control. 
 
Fig. 4 (A) Intestinal transit after oral administration of non-absorbed marker in 
wild-type mice with or without pretreatment of CSS. The rate of transit was determined 
as indicated in the legend of Fig 3A. GIP or SST or saline was administered 
intraperitoneally 15-min prior to the administration of non-absorbed marker. CSS or 
 29 
saline was intraperitoneally administered 10-min prior to GIP administration. Data are 
shown as means with S.E.M. (n=6 for each group). Statistical significance was 
determined using students’ t test. **P<0.01 compared with control. ***P<0.01 
compared with GIP alone administered mice. (B) Inhibition of glucose absorption by 
GIP in wild-type mice with or without pretreatment of CSS, and inhibition of glucose 
absorption by SST. CSS or saline was intraperitoneally administered 10-min prior to 
GIP administration. Data are shown as means with S.E.M. (n=6 for each group). 
Statistical significance was determined using students’ t test. *P<0.05 compared with 
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